Holen Sie sich die Stockscreener-App
16.06
5.91%
0.89
Schlusskurs vom Vortag:
$15.17
Offen:
$15.1
24-Stunden-Volumen:
12,975
Relative Volume:
0.27
Marktkapitalisierung:
$410.55M
Einnahmen:
$59,000
Nettoeinkommen (Verlust:
$-21.81M
KGV:
-1.4664
EPS:
-10.9518
Netto-Cashflow:
$-18.07M
1W Leistung:
+4.60%
1M Leistung:
+15.58%
6M Leistung:
+43.06%
1J Leistung:
+114.79%
1-Tages-Spanne:
$15.10
$16.61
1-Wochen-Bereich:
$15.02
$16.70
52-Wochen-Spanne:
$5.742
$16.90
Benitec Biopharma Inc Stock (BNTC) Company Profile
Firmenname
Benitec Biopharma Inc
Sektor
Branche
Telefon
(510) 780-0819
Adresse
3940 TRUST WAY, HAYWARD, CA
Vergleichen Sie BNTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
16.04 | 399.11M | 59,000 | -21.81M | -18.07M | -10.95 |
|
ONC
Beone Medicines Ltd Adr
|
256.85 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.75 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.31 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
497.31 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-12 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-05 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-02-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-12-31 | Bestätigt | Maxim Group | Buy |
| 2015-09-16 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Benitec Biopharma Inc Aktie (BNTC) Neueste Nachrichten
Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Position Boosted by Ameriprise Financial Inc. - Defense World
Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Form 424B3 Benitec Biopharma Inc. - StreetInsider
Northern Trust Corp Grows Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trials - Investing.com Nigeria
(BNTC) Investment Report - news.stocktradersdaily.com
Benitec Biopharma (BNTC) Files to Sell 900K Shares - GuruFocus
Benitec Biopharma (BNTC) Proposes Sale of 900K Common Shares | B - GuruFocus
Benitec Biopharma (BNTC) Proposes Sale of 900K Common Shares | BNTC Stock News - GuruFocus
FY2025 EPS Forecast for Benitec Biopharma Raised by Analyst - Defense World
Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet - Yahoo Finance
Benitec Biopharma (NASDAQ:BNTC) Receives “Buy” Rating from HC Wainwright - Defense World
Benitec Biopharma (BNTC) Receives Buy Rating from HC Wainwright & Co. | BNTC Stock News - GuruFocus
Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year? - Yahoo Finance
Leerink Partnrs Issues Optimistic Forecast for BNTC Earnings - Defense World
Benitec Biopharma (NASDAQ:BNTC) Earns Market Outperform Rating from JMP Securities - Defense World
(BNTC) Trading Signals - news.stocktradersdaily.com
Benitec Biopharma (BNTC) Analyst Rating Update from JMP Securities | BNTC Stock News - GuruFocus
Benitec stock holds $20 target, Market Outperform rating - Investing.com
Benitec stock holds $20 target, Market Outperform rating By Investing.com - Investing.com India
Benitec (BNTC) Advances BB-301 Treatment for OPMD with Promising Clinical Progress | BNTC Stock News - GuruFocus
Benitec Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Benitec Biopharma Q3 Operating Income USD -10.2 Million - marketscreener.com
Benitec Biopharma Releases Third Quarter 2025 Financial Results - GuruFocus
Benitec Biopharma reports Q3 EPS (24c) vs. (23c) last year - TipRanks
Benitec Biopharma Inc. SEC 10-Q Report - TradingView
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2025 - marketscreener.com
Benitec Biopharma Releases Third Quarter 2025 Financial Results | BNTC Stock News - GuruFocus
Benitec Biopharma (BNTC) Expected to Announce Quarterly Earnings on Monday - Defense World
How To Trade (BNTC) - news.stocktradersdaily.com
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Shares Purchased by Geode Capital Management LLC - Defense World
Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade - MSN
What Makes Benitec Biopharma (BNTC) a New Buy Stock - Yahoo Finance
(BNTC) Long Term Investment Analysis - news.stocktradersdaily.com
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? - Yahoo Finance
Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha
JMP Securities Boosts Benitec Biopharma (NASDAQ:BNTC) Price Target to $20.00 - Defense World
Benitec Biopharma (BNTC) Stock Price Target Increased Amid Promi - GuruFocus
Benitec stock price target raised to $20 at JMP Securities - Investing.com Australia
Benitec stock price target raised to $20 at JMP Securities By Investing.com - Investing.com India
Finanzdaten der Benitec Biopharma Inc-Aktie (BNTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Benitec Biopharma Inc-Aktie (BNTC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):